BioNTech (BNTX) Stock May Be Fully Valued Despite Fresh Oncology Data Preview

BioNTech has seen its share price move around in recent years, and with the focus increasingly on its oncology pipeline, the key question now is whether the current valuation is still aligned with the revenue base behind it. For anyone watching the stock, the issue is less about headlines and more about what today’s price implies for the business that generates those sales. Over the past 5 years the stock has fallen 66.9%. This puts the spotlight squarely on whether the market is now valuing...